open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-20
Get Citation

Molecular diagnostic in a patient with adenocarcinoma of the lung treated with erlotinib

Sławomir Mańdziuk, Magdalena Wójcik-Superczyńska

open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-20

Abstract

Activating mutations of epidermal growth factor receptor gene (EGFR) are most frequently detected in patients with adenocarcinoma histology. The detection of somatic mutations becomes a diagnostic standard and allows qualify non-small-cell lung cancer (NSCLC) patients, and especially adenocarcinoma patients with EGFR activating mutations for molecularly targeted therapy against EGFR tyrosine kinase (TKI-EGFR). Development of molecular biology techniques allows using sensitive methods for EGFR mutation analysis as well as detection of mutations in heterozygous materials (tumor tissue samples or cytology samples). Detection of EGFR activating mutation and treatment of patients with TKI-EGFR agents allows to expend a progression-free survival (PFS) as well as better tolerance of therapy. Unfortunately, the early progression of the disease may appears during treatment, what is caused by development of acquired resistance to TKI-EGFR therapy.

Abstract

Activating mutations of epidermal growth factor receptor gene (EGFR) are most frequently detected in patients with adenocarcinoma histology. The detection of somatic mutations becomes a diagnostic standard and allows qualify non-small-cell lung cancer (NSCLC) patients, and especially adenocarcinoma patients with EGFR activating mutations for molecularly targeted therapy against EGFR tyrosine kinase (TKI-EGFR). Development of molecular biology techniques allows using sensitive methods for EGFR mutation analysis as well as detection of mutations in heterozygous materials (tumor tissue samples or cytology samples). Detection of EGFR activating mutation and treatment of patients with TKI-EGFR agents allows to expend a progression-free survival (PFS) as well as better tolerance of therapy. Unfortunately, the early progression of the disease may appears during treatment, what is caused by development of acquired resistance to TKI-EGFR therapy.

Get Citation

Keywords

EGFR, erlotinib, non-small-cell lung cancer, RT-PCR, resistance

About this article
Title

Molecular diagnostic in a patient with adenocarcinoma of the lung treated with erlotinib

Journal

Oncology in Clinical Practice

Issue

Vol 10, Supp. G (2014)

Pages

11-13

Published online

2015-03-20

Keywords

EGFR
erlotinib
non-small-cell lung cancer
RT-PCR
resistance

Authors

Sławomir Mańdziuk
Magdalena Wójcik-Superczyńska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl